Payment overview · 2025
General Payments
$897.76
45 reported records · 15 companies
Healthcare provider profile · identity verified
John Eric Ammon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1215973524
Verified facts
What the public records show
CMS Open Payments records show John Eric Ammon, M.D. received $897.76 in general payments during 2025 across 45 reported records.
PFIZER INC. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $274.39 | 30.6% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $125.73 | 14.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $102.36 | 11.4% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.50 | 6.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.46 | 6.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.06 | 5.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.45 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.93 | 4.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.41 | 3.3% | 2 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $22.83 | 2.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.53 | 2.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.81 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.53 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.92 | 2.0% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $14.85 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.76 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $148.26 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $148.26 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.13 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $125.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $114.40 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.36 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.34 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $80.12 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.50 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.06 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.93 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.41 | 2 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $11.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 350 | 110 |
| Losartan Potassium | Losartan Potassium | 325 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 86 |
| Gabapentin | Gabapentin | 165 | 35 |
| Eliquis | Apixaban | 135 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 46 |
| Lisinopril | Lisinopril | 128 | 38 |
| Ozempic | Semaglutide | 113 | 19 |
| Potassium Chloride | Potassium Chloride | 113 | 37 |
| Mounjaro | Tirzepatide | 108 | 13 |
| Omeprazole | Omeprazole | 108 | 31 |
| Furosemide | Furosemide | 105 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 29 |
| Meloxicam | Meloxicam | 102 | 35 |
| Valsartan | Valsartan | 98 | 25 |
| Simvastatin | Simvastatin | 97 | 29 |
| Sertraline Hcl | Sertraline Hcl | 94 | 28 |
| Clonazepam | Clonazepam | 93 | 13 |
| Trazodone Hcl | Trazodone Hcl | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 19 |
| Montelukast Sodium | Montelukast Sodium | 86 | 26 |
| Allopurinol | Allopurinol | 82 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 23 |
| Spironolactone | Spironolactone | 77 | 21 |
| Metformin Hcl | Metformin Hcl | 74 | 21 |
| Carvedilol | Carvedilol | 72 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 15 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Famotidine | Famotidine | 58 | 21 |
| Synthroid | Levothyroxine Sodium | 58 | 12 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Donepezil Hcl | Donepezil Hcl | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 17 |
| Alprazolam | Alprazolam | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Metformin Hcl Er | Metformin Hcl | 46 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 15 |
| Atenolol | Atenolol | 39 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 17 |
| Methocarbamol | Methocarbamol | 38 | 26 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 38 | suppressed |
| Prednisone | Prednisone | 37 | 24 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 15 |
| Azithromycin | Azithromycin | 27 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 11 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 13 |
| Estradiol | Estradiol | 18 | 11 |
| Methylprednisolone | Methylprednisolone | 18 | 14 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $897.76 · 45 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Kerendia, Kimyrsa, MONOFERRIC, MOUNJARO, NURTEC ODT, OTEZLA, Orbactiv, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rezzayo, Rybelsus, SHINGRIX, UBRELVY, Veozah, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error